Journal of Gastrointestinal Cancer最新文献_第2页

The Significance of Screening Endoscopy at 2-Year Interval for Detecting Pharyngeal and Esophageal Cancer in the Japanese General Population. 在日本普通人群中，2年一次的内镜筛查对检测咽喉癌和食管癌的意义。

IF 1.6

Journal of Gastrointestinal Cancer Pub Date : 2025-05-10 DOI: 10.1007/s12029-025-01243-7

Kazuhiro Kashiwagi, Toshifumi Yoshida, Satoshi Kinoshita, Hiromasa Nakamizo, Rieko Nakamura, Hiromasa Takaishi, Yasushi Iwao, Takanori Kanai

{"title":"The Significance of Screening Endoscopy at 2-Year Interval for Detecting Pharyngeal and Esophageal Cancer in the Japanese General Population.","authors":"Kazuhiro Kashiwagi, Toshifumi Yoshida, Satoshi Kinoshita, Hiromasa Nakamizo, Rieko Nakamura, Hiromasa Takaishi, Yasushi Iwao, Takanori Kanai","doi":"10.1007/s12029-025-01243-7","DOIUrl":"10.1007/s12029-025-01243-7","url":null,"abstract":"Purpose: We previously identified examination time and 2-year interval as effective quality indicators for detecting upper gastrointestinal cancer during screening esophagogastroduodenoscopy (EGD). We evaluated the significance of biennial endoscopy in detecting pharyngeal and esophageal cancer.Methods: Individuals who underwent multiple EGD examinations as health checkups at our center between August 2012 and January 2022 were included. Endoscopists were categorized into two groups based on their mean examination time for normal EGD findings, using a threshold of 5 min. The associations between cancer detection rate and these indicators were analyzed using multivariable analyses.Results: Twelve endoscopists performed more than 1000 examinations each, for a total of 28,842 examinations, detecting all (6 pharyngeal and 26 esophageal) cancers. Intervals between endoscopies were classified into three groups: ≤ 1 year (Group 1), 1 to ≤ 2 years (Group 2), and > 2 years (Group 3). This cancer detection rate did not differ significantly between Groups 1 and 2 (p = 0.761) but was significantly higher in Group 3 than in Group 2 (OR = 4.356, 95% CI = 1.161-16.333, p = 0.029). When Groups 1 and 2 were combined (≤ 2 years) and compared with Group 3, an interval of > 2 years was significantly associated with a higher detection rate, including cases not curable by endoscopic resection (OR, 4.710; 95% CI, 1.806-12.282; p = 0.002). Examination time was not associated with the cancer detection rate (p = 0.944).Conclusions: These findings support the significance of biennial endoscopy in detecting pharyngeal and esophageal cancer as well.","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"114"},"PeriodicalIF":1.6,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Fecal Immunochemical Testing for Colorectal Cancer Prevention in Two Public Hospitals. 更正：两所公立医院粪便免疫化学检测预防大肠癌。

IF 1.6

Journal of Gastrointestinal Cancer Pub Date : 2025-05-10 DOI: 10.1007/s12029-025-01223-x

Changlin Gong, Maria Teresa Medina Rojas, Maria Gabriela Rubianes Guerrero, Michail Kladas, Arameh Mousakhanian, Aarushi Sudan, Adejoke Johnson, Kimberly Cartmill, Elana Sydney, Donald P Kotler

引用次数: 0

Neoadjuvant Pembrolizumab Enables Successful Downstaging and Resection of Borderline Resectable MSI-H/dMMR Pancreatic Ductal Adenocarcinoma: A Case Report and Literature Review. 新辅助派姆单抗能够成功降低分期和切除边缘可切除的MSI-H/dMMR胰腺导管腺癌：一例报告和文献回顾。

IF 1.6

Journal of Gastrointestinal Cancer Pub Date : 2025-05-08 DOI: 10.1007/s12029-025-01237-5

Kevin Zhao, Vijayaragavan Muralidharan, Shaun Brown, Anthony Upton, Moammar Alshimirti, Prasad D Cooray

{"title":"Neoadjuvant Pembrolizumab Enables Successful Downstaging and Resection of Borderline Resectable MSI-H/dMMR Pancreatic Ductal Adenocarcinoma: A Case Report and Literature Review.","authors":"Kevin Zhao, Vijayaragavan Muralidharan, Shaun Brown, Anthony Upton, Moammar Alshimirti, Prasad D Cooray","doi":"10.1007/s12029-025-01237-5","DOIUrl":"https://doi.org/10.1007/s12029-025-01237-5","url":null,"abstract":"Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a poor prognosis. While immunotherapy has shown limited efficacy in most PDAC cases due to an immunosuppressive tumour microenvironment, tumours with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) status exhibit increased responsiveness to immune checkpoint inhibitors.Case presentation: We report the case of a 45-year-old woman with Lynch syndrome who was diagnosed with MSI-H/dMMR PDAC during routine surveillance. Given the borderline resectable nature of her tumour and previous chemotherapy-related neurotoxicity, she was treated with neoadjuvant pembrolizumab instead of conventional chemotherapy. Following four cycles of pembrolizumab, imaging revealed a marked metabolic response, allowing for successful R0 pancreatoduodenectomy. Postoperative histology confirmed a significant reduction in tumour size, and immunohistochemical analysis demonstrated increased CD8 + T cell infiltration, supporting an enhanced anti-tumour immune response. The patient continues adjuvant pembrolizumab therapy without complications.Conclusion: This case highlights the potential role of neoadjuvant pembrolizumab in MSI-H/dMMR PDAC, demonstrating successful tumour downstaging and facilitating surgical resection. Our findings support further investigation into the integration of immunotherapy as a neoadjuvant strategy for select PDAC patients.","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"112"},"PeriodicalIF":1.6,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062155/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Association Between Health Literacy and Colorectal Cancer Screening: Findings Using a Three-Question Health Literacy Measure. 健康素养与结直肠癌筛查之间的关系：使用三问题健康素养测量的结果。

IF 1.6

Journal of Gastrointestinal Cancer Pub Date : 2025-05-08 DOI: 10.1007/s12029-025-01241-9

Alfonsus Adrian H Harsono, Rachel Ruiz, Meghna Katta, Hannah Ficarino Sheffer, Marshall Chandler McLeod, Smita Bhatia, Daniel I Chu, Robert H Hollis

{"title":"The Association Between Health Literacy and Colorectal Cancer Screening: Findings Using a Three-Question Health Literacy Measure.","authors":"Alfonsus Adrian H Harsono, Rachel Ruiz, Meghna Katta, Hannah Ficarino Sheffer, Marshall Chandler McLeod, Smita Bhatia, Daniel I Chu, Robert H Hollis","doi":"10.1007/s12029-025-01241-9","DOIUrl":"https://doi.org/10.1007/s12029-025-01241-9","url":null,"abstract":"Purpose: Health literacy (HL) can impact health behaviors including colorectal cancer (CRC) screening. Prior findings using extensive measures of HL suggested that low HL is associated with lower CRC screening rates. We hypothesized that low HL, when measured using a clinically applicable three-question measure, would also be associated with low CRC screening rates.Methods: Data collected from the 2016 Behavioral Risk Factor Surveillance System (BRFSS) was utilized from 17 states that included a three-question HL measure. Participants ages 50-75 were included. The HL scores were categorized as adequate, marginal, or limited HL. The primary outcome was United States Preventative Services Task Force (USPSTF) recommendation-concordant CRC screening. The relationship between HL and CRC screening was examined using multivariable logistic regression.Results: Among 38,044 participants who met inclusion criteria, 47.2% (n = 17,950), 49.9% (n = 18,989), and 2.9% (n = 1105) had adequate, marginal, and limited HL, respectively. Lower HL levels were associated with lower adherence to USPSTF CRC screening recommendations: 73.3% for adequate, 68.0% for marginal, and 48.9% for limited HL (p < 0.01). Respondents with limited HL were 45% less likely to undergo CRC screening (OR = 0.55; 95%CI: 0.48-0.63). A significant interaction (p < 0.01) between health literacy and sex was identified. CRC screening difference among HL levels was more pronounced for male (OR = 0.48; 95% CI: 0.40-0.79) than female respondents (OR = 0.63; 95% CI: 0.52-0.76).Conclusion: Limited health literacy is associated with significantly lower rates of appropriate CRC screening, particularly for males. This three-question HL measure provides a clinically applicable tool to identify people at risk for lack of CRC screening.","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"111"},"PeriodicalIF":1.6,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Submucosal Tunneling Endoscopic Resection for Upper Gastrointestinal Subepithelial Lesions: A Systematic Review and Meta-Analysis. 粘膜下隧道内镜切除上消化道上皮下病变：系统回顾和荟萃分析。

IF 1.6

Journal of Gastrointestinal Cancer Pub Date : 2025-04-29 DOI: 10.1007/s12029-025-01235-7

Stavros Chrysovalantis Liapis, Ioannis Baloyiannis, Konstantinos Perivoliotis, Dimitrios Lytras, George Tzovaras

{"title":"Submucosal Tunneling Endoscopic Resection for Upper Gastrointestinal Subepithelial Lesions: A Systematic Review and Meta-Analysis.","authors":"Stavros Chrysovalantis Liapis, Ioannis Baloyiannis, Konstantinos Perivoliotis, Dimitrios Lytras, George Tzovaras","doi":"10.1007/s12029-025-01235-7","DOIUrl":"https://doi.org/10.1007/s12029-025-01235-7","url":null,"abstract":"Aim: Submucosal tunneling endoscopic resection (STER) is an advanced endoscopic technique used for the minimally invasive removal of subepithelial lesions of the gastrointestinal (GI) tract. The aim of this study was to evaluate the safety and efficacy of STER for upper gastrointestinal subepithelial lesions.Methods: A comprehensive search of major scholar databases (until December 15, 2023) was performed. Complete resection rate was considered the primary outcome. En bloc resection, operation duration, length of stay (LOS), local recurrence, and periprocedural complications were considered secondary outcomes. Random-effects (RE) and fixed-effects (FE) models were used to generate the outcome estimates.Results: A total of 37 studies and 3795 patients were included. Pooled proportion of complete resection was 99% (95% CI 98.4-99.6%, p < 0.001). En bloc resection was achieved at 87.7% of cases. Overall mean operation duration was 64.2 min, while mean LOS was estimated at 4.93 days. The local recurrence rate was 0.1%. The two most common complications associated with STER were subcutaneous emphysema (5.5%) and pneumothorax (3%).Conclusion: STER is a highly feasible and safe treatment modality for upper GI subepithelial lesions.","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"110"},"PeriodicalIF":1.6,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multidisciplinary Management of Anorectal Melanoma: a Retrospective Analysis of Surgical and Systemic Therapies from the National Cancer Database. 肛肠黑色素瘤的多学科管理：来自国家癌症数据库的手术和全身治疗的回顾性分析。

IF 1.6

Journal of Gastrointestinal Cancer Pub Date : 2025-04-28 DOI: 10.1007/s12029-025-01234-8

Richard Sassun, Annaclara Sileo, Jyi Cheng Ng, Davide Ferrari, Matthew S Block, William R G Perry, Nicholas P McKenna, Kristen K Rumer, David W Larson

{"title":"Multidisciplinary Management of Anorectal Melanoma: a Retrospective Analysis of Surgical and Systemic Therapies from the National Cancer Database.","authors":"Richard Sassun, Annaclara Sileo, Jyi Cheng Ng, Davide Ferrari, Matthew S Block, William R G Perry, Nicholas P McKenna, Kristen K Rumer, David W Larson","doi":"10.1007/s12029-025-01234-8","DOIUrl":"https://doi.org/10.1007/s12029-025-01234-8","url":null,"abstract":"Purpose: Anorectal melanoma (ARM) represents a problematic scenario due to a 5-year overall survival (OS) rate below 20% and its increasing incidence. Due to its comparable OS, local surgery (LS) has replaced radical surgery (RS). Adjuvant chemotherapy (Adj-CHT) and adjuvant immunotherapy (Adj-IT) are common treatments for ARM, while neoadjuvant immunotherapy (Neo-IT) has not been investigated yet. This study aimed to determine the best treatment to improve the OS.Methods: Patients with non-metastatic ARM in the National Cancer 1Database (2011-2021) who underwent surgery and received Neo-IT, Adj-IT, or Adj-CHT were included. Two cohorts were created based on the surgical approach (LS or RS). In their respective cohorts, patients receiving Neo-IT, Adj-IT, or Adj-CHT were matched 1:1:1 based on age, tumor size and location, lymphovascular invasion, and nodal disease. Kaplan-Meier analyses compared the different groups' influence on the 3-year OS.Results: Sixty patients were included in the LS cohort. Among them, there was no difference in the 3-year OS at the Kaplan-Meier analysis (Neo-IT 61%, Adj-IT 47.1%, and Adj-CHT 44%). Thirty-six patients were included in the RS cohort. Kaplan-Meier analysis for this group revealed that Neo-IT was a protective factor for 3-year OS (Neo-IT 71%, Adj-IT 11%, Adj-CHT 8%; p-value = 0.002).Conclusion: Neo-IT + RS seems to improve the 3-year OS compared to the other common treatments for ARM. Neo-IT + RS can be considered a valuable treatment since prospective trials are challenging for rare diseases. When RS is not feasible, Neo-IT + LS may be beneficial as the 3-year OS reaches 61%.","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"108"},"PeriodicalIF":1.6,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Efficacy and Safety of Nivolumab Combined with Nab-Paclitaxel or Oxaliplatin as a First-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer. 纳武单抗联合nab -紫杉醇或奥沙利铂作为晚期或转移性胃癌和胃食管结癌一线治疗的有效性和安全性

IF 1.6

Journal of Gastrointestinal Cancer Pub Date : 2025-04-28 DOI: 10.1007/s12029-025-01211-1

Juan Li, Shuman Li, Ying Zhang, Sisi Ye, Rongrui Liu, Weiwei Shi

{"title":"The Efficacy and Safety of Nivolumab Combined with Nab-Paclitaxel or Oxaliplatin as a First-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer.","authors":"Juan Li, Shuman Li, Ying Zhang, Sisi Ye, Rongrui Liu, Weiwei Shi","doi":"10.1007/s12029-025-01211-1","DOIUrl":"https://doi.org/10.1007/s12029-025-01211-1","url":null,"abstract":"Objective: This study aims to assess the therapeutic efficacy and safety of nivolumab combined with chemotherapy as a first-line treatment for advanced or metastatic gastric cancer, specifically comparing the outcomes of oxaliplatin-based versus albumin-bound paclitaxel (nab-paclitaxel)-based therapies.Methods: We retrospectively analyzed 93 patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma treated at the First Medical Center of Chinese PLA General Hospital from September 2017 to November 2022. Patients were categorized into the nivolumab + oxaliplatin (N-OX group) or nivolumab + nab-paclitaxel (N-AP group) based on the chemotherapy regimen. Progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety were evaluated as endpoints.Results: At the end of the follow-up period on September 31, 2023, we reported an ORR of 65.6% and DCR of 95.7% across all patients. The median PFS was 8.4 months, with no significant difference between the N-OX and N-AP groups (median, 7.8 vs 9.5 months; P = 0.450). Notably, patients with diffuse gastric cancer in N-AP group showed a 44.7% reduction in tumor progression risk compared with the N-OX group (P = 0.046). The overall safety profile was acceptable in two groups.Conclusions: Our study suggested that nivolumab combined with chemotherapy was effective and safe as a first-line intervention for advanced gastric cancer. While both oxaliplatin and nab-paclitaxel regimens showed similar efficacy, the nab-paclitaxel may offer additional benefits for patients with diffuse gastric cancer. Further research is encouraged to confirm these findings and refine treatment strategies.","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"109"},"PeriodicalIF":1.6,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can Chemotherapy Facilitate Less Morbid Surgery in Multicentric Intra-abdominal Inflammatory Myofibroblastic Tumor? 化疗能促进多中心腹内炎性肌纤维母细胞瘤的低发病率手术吗？

IF 1.6

Journal of Gastrointestinal Cancer Pub Date : 2025-04-24 DOI: 10.1007/s12029-025-01230-y

Devesh S Ballal, Poonam Panjwani, Samreen S Qureshi, Sajid S Qureshi

{"title":"Can Chemotherapy Facilitate Less Morbid Surgery in Multicentric Intra-abdominal Inflammatory Myofibroblastic Tumor?","authors":"Devesh S Ballal, Poonam Panjwani, Samreen S Qureshi, Sajid S Qureshi","doi":"10.1007/s12029-025-01230-y","DOIUrl":"https://doi.org/10.1007/s12029-025-01230-y","url":null,"abstract":"Background: Inflammatory myofibroblastic tumor is a rare benign neoplasm affecting young adults and children. Although often considered benign, its locally aggressive nature and tendency to recur make its management immensely challenging, particularly without robust evidence to guide treatment. Surgical excision offers the best hope for a cure; however, this can lead to significant morbidity and may not always be possible, especially for multicentric diseases.Case presentation: We report a multicentric abdominal inflammatory myofibroblastic tumor in a 6-year-old girl who presented with massive abdominal distention. The sheer size of the mass, coupled with multicentric presentation and absent mobility on clinical examination, would have led to a very morbid surgical exploration. This patient was treated with initial chemotherapy, which led to a dramatic response in both symptoms and size of masses, facilitating a complete surgical resection with negligible postoperative morbidity.Conclusions: Although surgery is the preferred treatment for a resectable disease, initial chemotherapy for multicentric or locally advanced inflammatory myofibroblastic tumors facilitates complete surgical resection.","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"107"},"PeriodicalIF":1.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12021936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pancreatic Acinar Cell Carcinoma: Demographics, Treatment, and Survival Outcomes, A Retrospective Population-Based Study. 胰腺腺泡细胞癌：人口统计学、治疗和生存结果，一项基于人群的回顾性研究。

IF 1.6

Journal of Gastrointestinal Cancer Pub Date : 2025-04-23 DOI: 10.1007/s12029-025-01233-9

Abdul Qahar Khan Yasinzai, Asif Iqbal, Diego Olavarria-Bernal, Kalyani Ballur, Agha Wali, Shalini Ballur, Bisma Tareen, Marjan Khan, Hritvik Jain, Israr Khan, Nooran Fadhil, Amir Humza Sohail, Asad Ullah

{"title":"Pancreatic Acinar Cell Carcinoma: Demographics, Treatment, and Survival Outcomes, A Retrospective Population-Based Study.","authors":"Abdul Qahar Khan Yasinzai, Asif Iqbal, Diego Olavarria-Bernal, Kalyani Ballur, Agha Wali, Shalini Ballur, Bisma Tareen, Marjan Khan, Hritvik Jain, Israr Khan, Nooran Fadhil, Amir Humza Sohail, Asad Ullah","doi":"10.1007/s12029-025-01233-9","DOIUrl":"https://doi.org/10.1007/s12029-025-01233-9","url":null,"abstract":"Purpose: Pancreatic acinar cell carcinoma accounts for 1-2% of pancreatic tumors, with increasing frequency in recent years, and still represents a poor prognosis. This study aims to expand and update existing literature by analyzing national data gathered over almost two decades.Methods: Data from 488 patients diagnosed with PACC in the Surveillance, Epidemiology, and End Results database were analyzed. This study employed the Cox regression method to compute hazard ratios and identify independent factors influencing survival. Additionally, Kaplan-Meier survival curves were utilized alongside the log-rank test.Results: The median age was 64.7 years with male predilection (70.5%). \"Poorly differentiated carcinoma\" was the most common subtype (45.8%). The liver was the most common site of metastases (31.3%). The 5-year observed overall survival (OS) rate was 19.2% (95% CI, 14.9-23.8). The 5-year cause-specific survival (CSS) rate was 22.4% (95% CI, 17.7-27.5). Male gender has a 5-year OS of 19.2% (95% CI, 14.0-25.1) compared to female OS of 30.2% (95% CI, 20.7-40.1). Patients treated with multimodal therapy (surgery with chemoradiation) over only surgery or chemotherapy had better 5-year OS, 53.5% (95% CI, 31.8-71.0). Age > 60 and distant stage were independent factors associated with increased mortality.Conclusion: Pancreatic acinar cell carcinoma is a rare, aggressive form of pancreatic cancer that primarily affects older adults. Our findings offer valuable insights to guide future clinical guidelines and tailored treatment strategies.","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"106"},"PeriodicalIF":1.6,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Homologous Recombination Deficiency Is Associated with Shorter Survival in Colorectal Cancer Patients. 同源重组缺陷与结直肠癌患者较短的生存期相关

IF 1.6

Journal of Gastrointestinal Cancer Pub Date : 2025-04-22 DOI: 10.1007/s12029-025-01231-x

Xuan Zhang, Pan Zhang, Hua Dong, Lin Li, Lingling Lu, Hongyuan Lv, Xin Yu, Hong Yu

{"title":"Homologous Recombination Deficiency Is Associated with Shorter Survival in Colorectal Cancer Patients.","authors":"Xuan Zhang, Pan Zhang, Hua Dong, Lin Li, Lingling Lu, Hongyuan Lv, Xin Yu, Hong Yu","doi":"10.1007/s12029-025-01231-x","DOIUrl":"https://doi.org/10.1007/s12029-025-01231-x","url":null,"abstract":"Background: Colorectal cancer (CRC) patients benefit more from immune checkpoint inhibitor therapy, but they only account for around 15% of all patients. The remaining patients still lack effective therapeutic biomarkers to predict their prognosis.Methods: We performed whole-exome sequencing (WES) to analyze 84 CRC specimens, classifying them into different groups based on their microsatellite status (MS), tumor mutation burden (TMB), homologous recombination deficiency (HRD) score, and clinicopathological features, which might be associated with clinical outcomes. Survival analysis and multivariable Cox regression modeling were employed to identify prognostic indicators. Comparative genomic profiling evaluated somatic mutations, copy number variations (CNVs), and pathway activation patterns across clinical subgroups.Results: The characteristics of the cohort (N = 84) revealed a median age of 52 years, with a male predominance (61.9%) and a majority of patients presenting with stage IV disease (77%). The HRD-high (HRD-H) subgroup accounted for 16.7%, while 19.0% of cases were microsatellite instability-high (MSI-H) and 22.6% were TMB-high (TMB-H). Multivariable analysis identified HRD-H as an independent predictor of overall survival (OS: HR = 0.19, 95% CI 0.12-0.94, p = 0.002). Comparative genomics demonstrated distinct mutation landscapes between HRD-H and HRD-low subgroups. In microsatellite-stable (MSS) patients, HRD-H status correlated with enriched SMAD4 mutations (p < 0.01) and differential activation of TGF-β/MYC signaling pathways compared to HRD-H-MSI counterparts.Conclusion: HRD status serves as a novel independent prognostic biomarker in CRC. Our multi-parametric genomic framework delineates stratification-specific molecular signatures, advocating for HRD-integrated molecular diagnostics to optimize CRC management.","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"105"},"PeriodicalIF":1.6,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0